Categories AlphaGraphs, Earnings, LATEST, Retail

Helen of Troy smashes market estimates; raises outlook

Helen of Troy Limited (HELE) topped market estimates on revenues and earnings for the second quarter of 2019, lifting the stock by more than 4% during premarket hours on Tuesday.

The consumer products company reported a 14.1% growth in consolidated net sales revenue to $393.5 million from the same period last year. The sales increase reflected higher brick-and-mortar sales in the Housewares and Health & Home segments along with growth in online and international sales.

Net income from continuing operations was $44 million or $1.66 per diluted share compared to $34.6 million or $1.26 per diluted share in the prior-year period. Adjusted net income was $52.5 million or $1.98 per diluted share.

Helen of Troy second quarter 2019 Earnings Infographic
Helen of Troy Q2 2019 Earnings Infographic

The quarterly results benefited from strategic investments in Leadership Brands and infrastructure. Net sales in Leadership Brands maintained its growth trajectory, increasing 20.5% during the quarter while sales in the online channel grew 16.1%.

Net sales improved in the Housewares and Health & Home segments, driven by various factors including point of sale growth with existing domestic customers, new product introductions and higher sales of seasonal products. The Beauty segment saw a decline in net sales mainly due to lower brick-and-mortar sales and rationalization of certain brands and products.

The company is increasing its outlook for full-year 2019 and now expects consolidated revenues of $1.53 billion to $1.56 billion, which reflects a sales growth of 3.8% to 5.5%. Consolidated GAAP diluted EPS from continuing operations is expected to be $6.31 to $6.46 and adjusted diluted EPS is expected to be $7.65 to $7.90.

For the Housewares segment, sales are expected to grow 9% to 11% and in Health & Home, sales are expected to grow 5% to 7%. Net sales in the Beauty segment are expected to decline in the low to mid single-digits.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top